You are here: Controversies / Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry / Charles M. Beasley’s commentary / Christian Fibiger’s comment on Charles M. Beasley's Comment
Sunday, 27.05.2018

Christian Fibiger’s comment on Charles M. Beasley's Comment

Barry Blackwell: Corporate Corruption in the Psychopharmaceutical Industry

 

 

Apart from one point that Dr. Beasley tangentially alludes to (and the importance of which is not widely appreciated), I don’t have much to add to his very thoughtful, well documented Commentary. That point is that given the ever increasing number of drugs that have become generic, the bar for successful innovation in drug discovery and development is constantly rising. Payers will rightly only pay a premium for drugs that are superior, either in safety or efficacy, to what generics can offer. The rising innovation bar inevitably leads to higher molecule attrition rates, and these in turn result in higher overall R & D costs regardless of how they are calculated. Hence, in the absence of disruptive technologies in drug discovery or new approaches to drug development, R & D costs will continue to rise in the future.

June 22, 2017